Navigation Links
Codexis Names Sarret SVP, Corporate Development
Date:3/18/2009

REDWOOD CITY, Calif., March 18 /PRNewswire/ -- Codexis, Inc. today announced that Joseph Sarret, M.D., J.D., has been promoted to Senior Vice President, Corporate Development from his previous position as Vice President, Corporate Development. He continues to report to Alan Shaw, Ph.D., President and CEO.

Dr. Sarret was named Vice President, Corporate Development in 2007. He joined Codexis in 2005 as Corporate Counsel and Director, Business Development. Previously, he was an associate at Latham & Watkins LLP, where he provided legal services to life sciences companies. He also served as attending physician and later Acting Medical Director for the HIV Clinic at the University of California, San Francisco Medical Center. Dr. Sarret is a graduate of both the University of California, San Francisco School of Medicine and Stanford Law School. He received a bachelor's degree in human biology from Stanford, where he graduated Phi Beta Kappa.

"Under Joe Sarret's leadership, Codexis has established business partnerships with some of the world's premier companies in energy and pharmaceuticals," Dr. Shaw said. "He has played a significant role in the evolution of our biofuels collaboration with Shell, and in successful negotiations with leading life science companies now leveraging Codexis technology in their human therapeutics programs. His continuing contributions to building a strong business base for Codexis are important to maintaining our leadership in clean technology."

Codexis, Inc. is a clean technology company. The company develops industrial biocatalysts, including enzymes and microbes. Codexis technology is used in the energy industry to enable next generation, non-food biofuels and by global pharmaceutical companies for cost-effective manufacturing of human therapeutics. Future commercial applications include carbon management, water treatment and chemical manufactu
'/>"/>

SOURCE Codexis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Irelands Allergy Standards Limited Adds Two New U.S. Names to Line-Up of Companies Making Allergy-Certified Consumer Products
2. New Corporate Agreement with Legacy Hospital Partners, Inc. Names Broadlane Exclusive Provider of Supply Chain and Procurement Services
3. Align Technology Names Sheila Tan as VP, Marketing and Chief Marketing Officer
4. ACP Medicine Names New Editor, Looks Toward Future of Medicine
5. VITAS Innovative Hospice Care(R) Names Karen Peterson Vice President and Chief Nursing Officer
6. NutraCea Names James C. Lintzenich As Interim CEO
7. Park Springs Names New Medical Director
8. Juvenile Diabetes Research Foundation Names Monye Connolly Corporate Chair for its Annual Walk to Cure Diabetes
9. SilverCensus.com Names Consumer Affairs Advocate, Healthcare Experts to Provide Free Educational Support for Seniors
10. Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors
11. National Electronic Attachment (NEA) Names EDI Health Group Top Clearinghouse for 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... 2015 Cambia Health Solutions and ... new, interactive Affordable Care Act (ACA) training course ... called “Affordable Care Act Expert Series, Large Group ... and consultative insights necessary to effectively engage and ... impacts of the ACA. , The interactive, experience-based ...
(Date:6/1/2015)... For years, facial plastic surgery demands ... like one would request a hairstyle, patients would use ... and more to illustrate their adaptation of choice. However, ... ushering in a new era of aesthetic envy – ... Rizk, MD, FACS notes that since the explosion of ...
(Date:6/1/2015)... Listen to Volvo’s Director of Connectivity Strategy, Martin ... granular data to create better customer oriented services. Flanking ... Josep Celaya Gonzalez, CIO at MAPFRE, and Silvan Rath, ... insurer, MAPFRE are well versed in capturing complex data ... driver. Award winning start-up ParkTAG offer an exciting new ...
(Date:6/1/2015)... A University of Texas at ... proteins that activate protein degradation, which helps to ... , The study published April 3rd in ... rats 2-3 months of age who performed resistance ... either whey protein (.4g/kg), low-dose Sustamine (.1g/kg), high-dose ...
(Date:6/1/2015)... June 01, 2015 Kurbo Health , ... children and teens, announced today it has added in-app ... for kids and teens to eat smart and reach their ... their coaches via text message and phone or video calls, ... through their in-app chat window. For paid users, they will ...
Breaking Medicine News(10 mins):Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 2Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 3Health News:Instagram Filters Launch New Facial Plastic Surgery Trend 2Health News:Complimentary Webinar: Volvo, MAPFRE and Award Winning Start-Up discuss new Frontier of In-Car Services 2Health News:Study Shows Taking Sustamine® L-Alanyl-L-Glutamine May Reduce Muscle Protein Breakdown After Resistance Exercise 2Health News:Study Shows Taking Sustamine® L-Alanyl-L-Glutamine May Reduce Muscle Protein Breakdown After Resistance Exercise 3Health News:Kurbo, First Mobile Weight Loss Program for Children and Teens, Enhances Coaching with New iOS In-App Chat and Messaging from Coaches 2
... for the AIDS Programme of Research in South Africa (CAPRISA) ... from the CAPRISA 004 microbicide study, which marks a significant ... as a whole. For years, antiretroviral medicines have been ... of the CAPRISA 004 study, we now have proof that ...
... researchers have discovered a previously unknown type of gene ... may lead to better insight about environmental exposure to ... journal Genome Research by researchers at The ... Hospital and Richard J. Solove Research Institute (OSUCCC-James), provides ...
... HealthDay Reporter , MONDAY, July 19 (HealthDay News) ... with the disorder are often slower to eat solid foods and ... However, the good news from the study is that the ... Problems with eating can emerge as early as infancy in ...
... and advocates from around the world today made a ... $US20 billion to the Global Fund to Fight AIDS, ... October. Because the level of replenishment committed at the ... 2011-2013, the meeting is widely viewed as the critical ...
... FAIRFAX, Va., July 16, 2010Framing climate change as a ... relevant, significant and understandable to members of the publiceven ... according to preliminary research by George Mason University,s Center ... conducted an exploratory study in the United States of ...
... Reporter , SUNDAY, July 18 (HealthDay News) -- Almost ... for HIV vaccines end up testing positive on routine ... a new study shows. The reason: They underwent ... possess immune system antibodies to the virus but not ...
Cached Medicine News:Health News:Anthony S. Fauci, M.D., on results from the CAPRISA 004 microbicide study 2Health News:Breast cancer cells regulate multiple genes in response to estrogen-like compounds 2Health News:Autistic Kids Often Fussier Eaters, but Nutrition OK 2Health News:Autistic Kids Often Fussier Eaters, but Nutrition OK 3Health News:Autistic Kids Often Fussier Eaters, but Nutrition OK 4Health News:AIDS 2010 delegates and speakers unite in support of full funding for the Global Fund, the next milestone in drive for universal access 2Health News:AIDS 2010 delegates and speakers unite in support of full funding for the Global Fund, the next milestone in drive for universal access 3Health News:AIDS 2010 delegates and speakers unite in support of full funding for the Global Fund, the next milestone in drive for universal access 4Health News:When climate change becomes a health issue, are people more likely to listen? 2Health News:Many False-Positive HIV Test Results for Those in AIDS Vaccine Trials 2Health News:Many False-Positive HIV Test Results for Those in AIDS Vaccine Trials 3
(Date:6/1/2015)... About Pressure Relief Devices ... and improve the quality life of patients who suffer ... a significant role in inhibiting the growth and treatment ... turn or rotate an immobile patient by providing all ... and specialty beds. These devices have the ability to ...
(Date:6/1/2015)... MECHANICSBURG, Pa. , June 1, 2015 ... announced that MJ Acquisition Corporation, a joint venture that ... Stowe XII, L.P., has completed its previously announced acquisition ... in the new joint venture. About ... leading operator of specialty hospitals and outpatient rehabilitation clinics ...
(Date:6/1/2015)... MENLO PARK, Calif. , June ... (OTCQX: DMPI) ("DelMar" and the "Company"), a ... cancer therapies in new orphan drug indications, today ... clinical trial of  VAL-083  (dianhydrogalactitol) in patients with ... deadly form of human brain cancer. ...
Breaking Medicine Technology:Global Pressure Relief Devices Market 2015-2019 2Global Pressure Relief Devices Market 2015-2019 3Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 2Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 2DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 4DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 5DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 6DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 7DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 8